Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Prescription Drug

Manchin, Schumer reach deal on climate, health, tax measure - Roll Call

A budget deal that West Virginia Democrat and the Senate majority leader had been discussing is officially back on the table.

Roll Call

Big decisions loom for Democrats' giant health bill

Democrats' high-stakes math game

Axios

Democrats' Manchin rage

They're furious with him but privately take him at his word that he's still committed to lowering prescription drug prices.

Axios

From analysis to the latest developments in health,
read the most diverse news in one place.

Biden OKs health care-focused budget pact struck in Senate

WASHINGTON — President Joe Biden on Friday endorsed a plan hatched by two key Senate Democrats to pass a budget reconciliation package that would help lower the cost of prescription drugs and protect millions of households from health insurance premium spikes, even if it leaves out important clean energy priorities.

Tribune News Service

Manchin rules out climate spending and tax hikes, but open to prescription drug reform

Manchin remains open to a much smaller bill that focuses on deficit reduction.

Axios

Commentary: Mark Cuban won’t fix our drug pricing problem

Mark Cuban, the billionaire “Shark Tank” celebrity and Dallas Mavericks owner, is getting attention again — this time for his Mark Cuban Cost Plus Drug Co., which seeks to reduce prescription drug prices for Americans. A new study finds that Medicare could have saved $3.6 billion in 2020 if it…

Los Angeles Times

AstraZeneca Says Imfinzi/Chemo Combo Shows Promising Action In Late-Stage Lung Cancer Study

AstraZeneca Plc (NASDAQ:AZN) announced high-level results from a planned interim analysis of the AEGEAN Phase 3 trial of Imfinzi (durvalumab) combined with neoadjuvant chemotherapy in patients with resectable non-small cell lung cancer (NSCLC). The data showed that Imfinzi plus neoadjuvant chemo before surgery demonstrated a statistically significant and meaningful improvement in pathologic complete…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

U.S. FDA Accepts Emergent's Anthrax Vaccine Candidate Filing For Review

The U.S. Food and Drug Administration (FDA) has accepted to review Emergent BioSolutions’ (NYSE: EBS) Biologics License Application (BLA) for its new anthrax vaccine candidate AV7909. The regulatory agency sets the Prescription Drug User Fee Act (PDUFA) goal date for a decision in month of April 2023.

Benzinga

Liz Weston: How to afford your meds and support your health

What you pay for a prescription drug varies enormously depending on your medication, pharmacy, insurance and other factors

The Independent UK

A handyman, wives, Escalades, ghost pharmacies: A $9 million Miami drug coupon fraud

MIAMI — Two Kendall men spent seven years — not even pausing during the two years one of them was in prison — raking in $9 million in a scam involving coupons meant to help people pay for prescription drugs. They used friends, wives of friends, shell companies and pharmacies…

Miami Herald

California wants to slash insulin prices by becoming a drugmaker. Can it succeed?

SACRAMENTO, Calif. — California is diving into the prescription drug business, attempting to achieve what no other state has done: produce its own brand of generic insulin and sell it at below-market prices to people with diabetes like Sabrina Caudillo.

Tribune News Service

Prices for new brand-name prescription drugs spike: Brigham and Women’s Hospital research

BOSTON — A new study out of Brigham and Women’s Hospital shows how newly marketed brand-name drugs in the U.S. are driving up health care spending, resulting in “detrimental effects for patient access and affordability.”

Boston Herald

FTC plans inquiry into pharmacy benefit manager practices

The Federal Trade Commission is starting an inquiry into the operations of pharmacy benefit managers who control access to prescription drugs for millions of Americans

The Independent UK

FDA Sounds Positive On Bluebird's One Gene Therapy But Doubts Another

The FDA signaled in briefing documents released that it may approve Bluebird bio Inc's (NASDAQ:BLUE) beti-cel gene therapy to treat β-thalassemia for those who require regular blood transfusions. The Prescription Drug User Fee Act (PDUFA) goal dates for beti-cel and eli-cel are August 19 and September 16. Bluebird bio's blood disorder treatment demonstrates "clinically meaningful"…

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Treasury Secretary Yellen says US faces ‘unacceptable levels of inflation’

Yellen says president’s proposed spending legislation could help lower costs for Americans, including for prescription drugs and clean energy initiatives

St. Louis Post-Dispatch

Editorial: A stronger federal medical privacy law could help protect abortion rights

Not long ago, Republicans in the Missouri Legislature were citing the need to protect patient privacy as the justification for blocking a statewide prescription drug database to address opioid addiction. Pro-privacy Republicans are suddenly in short supply now that patients’ rights are under direct attack in the abortion debate.

Tribune News Service

Medicare surprise: Drug plan prices touted during open enrollment can rise within a month

Something strange happened between the time Linda Griffith signed up for a new Medicare prescription drug plan during last fall’s enrollment period and when she tried to fill her first prescription in January.

ABC News

Less meth in Western Australia due to border closure leads to dangerous drug landscape change, support workers say

Frontline workers are encountering more people using heroin, benzodiazepines and other tranquillising prescription drugs in Western Australia after the state's border closure.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Axsome Poised To Receive FDA Rejection For Its Migraine Candidate, Shares Fall

The FDA has informed that Axsome Therapeutics Inc (NASDAQ:AXSM) chemistry, manufacturing, and controls issues identified during the review of AXS-07 remain unresolved. The Company is seeking approval for AXS-07 for the acute treatment of migraine. Based on the time remaining in the review cycle, the Company expects to receive a Complete Response Letter…

Kiplinger

11 Costly Medicare Mistakes You Should Avoid Making

If you don't make the right choices, you could end up with higher Medicare premiums and high out-of-pocket costs.

1 … 5 6 7 8

People

Chiquita BrooksLaSure

14 stories

Alex Oshmyansky

10 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.